Log In


All News

Sort By News Date & Time Sort Descending Order News Source News Title

  Refine Search  
Date Range
News Type

13/04/2015 6:05PM

Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders

Hydra Biosciences, Inc., a leader in the field of transient receptor potential (TRP) channel modulation, and Boehringer Ingelheim today announced that they have entered into a worldwide research collaboration and ...

12/01/2015 1:25PM

The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy

Boehringer Ingelheim today announced overall survival (OS) results were published in TheLancet Oncology from two independent Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6) in epidermal growth factor receptor ...

14/01/2015 9:45AM

Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas

Boehringer Ingelheim has announced collaboration with Yale University, New Haven, Connecticut, USA, with the goal of researching novel therapeutic targets in the field of immune-modulation. Immune-modulation refers ...

15/01/2015 9:35AM

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

Boehringer Ingelheim announced that it has established a research alliance with Vanderbilt University and the cancer drug discovery laboratory of Professor Stephen W. Fesik, Ph.D., the Orrin H. Ingram, II Chair in ...

15/01/2015 2:30PM

35 Partners from Industry and Academia to Join European Research Initiative for the Prevention of Alzheimer’s Dementia

The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s ...

19/01/2015 1:38PM

OFEV® (nintedanib*) approved in the EU for the treatment of IPF

Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHMP opinion on 20 ...

27/01/2015 2:55PM

New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD

For media outside the US, the UK and Canada   Boehringer Ingelheim today announced that the first patient has been enrolled into its large-scale DYNAGITO® study.1 It will assess the potential benefit of ...

01/06/2015 12:15PM

ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib* and ...